Skip to content
Subscriber Only

Teva Rebounds on Drug Study Amid Global Rally: Israel Overnight

Teva Pharmaceutical Industries Ltd. rose for the first day in four in U.S. trading as the clinical trial success of a medicine for attention deficit hyperactivity disorder outweighed concern that the company may lose patent litigation for its best-selling brand drug.

The American depositary receipts of the world’s largest maker of generic drugs climbed 2.5 percent yesterday to $40.33, the most in six trading sessions. The advance helped Teva’s New York-traded shares narrow their discount to Israeli shares to 4 cents, from 36 cents on Sept. 1.